title: Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation.
abstract: BACKGROUND
  Coronary artery disease (CAD) negatively impacts prognosis of patients undergoing surgical aortic valve replacement and revascularization is generally recommended at the time of surgery. Implications of CAD and preprocedural revascularization in the setting of transcatheter aortic valve implantation (TAVI) are not known.
  
  
  METHODS
  Patients who underwent successful TAVI from January 2005 to December 2007 were retrospectively divided into five groups according to the extent of CAD assessed with the Duke Myocardial Jeopardy Score: no CAD, CAD with DMJS 0, 2, 4, and > or =6. Study endpoints included 30-day and 1-year survival, evolution of symptoms, left ventricular ejection fraction (LVEF), and mitral regurgitation (MR) and need of revascularization during follow-up.
  
  
  RESULTS
  One hundred and thirty-six patients were included, among which 104 (76.5%) had coexisting CAD. Thirty-day mortality in the five study groups was respectively 6.3, 14.6, 7.1, 5.6, and 17.7% with no statistically significant difference between groups (P = 0.56). Overall survival rate at one year was 77.9% (95% CL: 70.9, 84.9) with no difference between groups (P = 0.63). Symptoms, LVEF, and MR all significantly improved in the first month after TAVI, but the extent of improvement did not differ between groups (P > 0.08). Revascularization after TAVI was uncommon.
  
  
  CONCLUSIONS
  The presence of CAD or nonrevascularized myocardium was not associated with an increased risk of adverse events in this initial cohort. On the basis of these early results, complete revascularization may not constitute a prerequisite of TAVI. This conclusion will require re-assessment as experience accrues in patients with extensive CAD.
authors.affiliation: St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Masson
authors.forename: May
authors.initials: M
authors.lastname: Lee
authors.forename: Robert H
authors.initials: RH
authors.lastname: Boone
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al Ali
authors.forename: Saad
authors.initials: S
authors.lastname: Al Bugami
authors.forename: Jaap
authors.initials: J
authors.lastname: Hamburger
authors.forename: G B
authors.initials: GB
authors.lastname: John Mancini
authors.forename: Jian
authors.initials: J
authors.lastname: Ye
authors.forename: Anson
authors.initials: A
authors.lastname: Cheung
authors.forename: Karin H
authors.initials: KH
authors.lastname: Humphries
authors.forename: David
authors.initials: D
authors.lastname: Wood
authors.forename: Fabian
authors.initials: F
authors.lastname: Nietlispach
authors.forename: John G
authors.initials: JG
authors.lastname: Webb
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000503:physiopathology; D001955:British Columbia; D006328:Cardiac Catheterization / Q000009:adverse effects / Q000401:mortality; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000150:complications* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006349:Heart Valve Diseases / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D019918:Heart Valve Prosthesis Implantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008297:Male; D008944:Mitral Valve Insufficiency / Q000209:etiology; D009204:Myocardial Revascularization; D016017:Odds Ratio; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013318:Stroke Volume; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left